Brad Fluegel
Healthcare advisor and educator, BMF Advisors LLC
Brad Fluegel currently advises health care organizations, entrepreneurs, and other participants in health care. He was most recently the senior vice president – chief healthcare commercial market development officer for Walgreen Co., based in Deerfield, Ill. Brad was responsible for all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Previously, he was Chief Strategy and Business Development officer for Walgreens, responsible for corporate strategy and business development.
Brad joined Walgreens in October 2012 after previously serving as executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint (now Anthem), among the nation’s largest health benefits companies. Prior to Wellpoint, Brad was senior vice president of national accounts and vice president, enterprise strategy at Aetna, Inc. Brad has also served as CEO Reden & Anders (Optum Consulting) and Tillinghast-Towers Perrin, a clinical, actuarial and management consulting practice that served all sectors of the healthcare industry. While there, he negotiated the sale of Tillinghast Health to Optum. He also held several roles in strategy, planning and product development and management at Harvard Community Health Plan and organized and led audits, feasibility studies and related projects for health care clients at Arthur Andersen & Co.
Brad currently serves on the Board of Directors of Metropolitan Jewish Health System in New York City, Performant Financial Corporation, Premera Blue Cross and AdhereHealth, among others. He also advises several health care companies and private equity firms. He served on the Fitbit Board of Directors until its sale to Google in early 2021, on the Board of Directors for Alight Solutions until its merger in July of 2021 and on the Board of Directors of Itamar Medical until it’s sale to Zoll Medical in December 2021.
Brad earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a bachelor of arts in business administration from the University of Washington. He also serves as a lecturer at the University of Pennsylvania’s Wharton School of Business.